Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irrisept is a wound debridement and cleansing system containing 0.05% chlorhexidine gluconate (CHG) in 99.5% sterile water. It is designed for mechanical irrigation and chemical antisepsis to reduce the risk of surgical site infections, particularly those caused by *Cutibacterium acnes* during orthopedic procedures such as primary shoulder arthroplasty. The solution provides broad-spectrum bactericidal activity by disrupting bacterial cell membranes and is effective against various antibiotic-resistant strains and biofilms. Developed by Irrimax Corporation and evaluated in clinical trials sponsored by Orthopaedic Associates of Michigan, Irrisept is used as a prophylactic measure to cleanse the surgical site and remove debris without damaging underlying tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Irrisept.